| Synergy of aromatic residues and phosphoserines within the intrinsically disordered DNA-binding inhibitory elements of the Ets-1 transcription factor G Desjardins, CA Meeker, N Bhachech, SL Currie, M Okon, BJ Graves, ... Proceedings of the National Academy of Sciences 111 (30), 11019-11024, 2014 | 50 | 2014 |
| NMR Structure of Varkud Satellite Ribozyme Stem−Loop V in the Presence of Magnesium Ions and Localization of Metal-Binding Sites, DO Campbell, P Bouchard, G Desjardins, P Legault Biochemistry 45 (35), 10591-10605, 2006 | 45 | 2006 |
| NMR structure of the A730 loop of the Neurospora VS ribozyme: insights into the formation of the active site G Desjardins, E Bonneau, N Girard, J Boisbouvier, P Legault Nucleic acids research 39 (10), 4427-4437, 2011 | 27 | 2011 |
| Role of SLV in SLI substrate recognition by the Neurospora VS ribozyme P Bouchard, J Lacroix-Labonté, G Desjardins, P Lampron, V Lisi, ... RNA 14 (4), 736-748, 2008 | 26 | 2008 |
| Conformational dynamics and the binding of specific and nonspecific DNA by the autoinhibited transcription factor Ets-1 G Desjardins, M Okon, BJ Graves, LP McIntosh Biochemistry 55 (29), 4105-4118, 2016 | 18 | 2016 |
| An integrative NMR-SAXS approach for structural determination of large RNAs defines the substrate-free state of a trans-cleaving Neurospora Varkud Satellite … P Dagenais, G Desjardins, P Legault Nucleic Acids Research 49 (20), 11959-11973, 2021 | 11 | 2021 |
| Anti-PD-1/LAG3 bispecific antibodies L Fayadat-Dilman, V Juan, S Khan, S Huang, H Ying, EE Cabrera, ... US Patent 11,072,658, 2021 | 6 | 2021 |
| Increasing the therapeutic index of IL12 by engineering for tumor specific protease activation JL Bishop, R Blackler, G Volkers, M Poffenberger, I Yu, J Smith, ... Cancer Research 81 (13_Supplement), 1788-1788, 2021 | 4 | 2021 |
| Structural characterization of DNA binding and autoinhibition by the ETS1 transcription factor G Desjardins University of British Columbia, 2015 | 2 | 2015 |
| Anti-pd-1/lag3 bispecific antibodies L Fayadat-Dilman, V Juan, S Khan, S Huang, H Ying, EE Cabrera, ... US Patent App. 17/384,561, 2021 | 1 | 2021 |
| Anti-pd-1/lag3 bispecific antibodies L Fayadat-Dilman, V Juan, S Khan, S Huang, H Ying, EE Cabrera, ... US Patent App. 17/384,539, 2021 | 1 | 2021 |
| HETERODIMERIC Fc VARIANTS SELECTIVE FOR Fc GAMMA RIIB E Escobar-Cabrera, G Lakatos, LG Presta, G Desjardins, ... US Patent App. 17/999,469, 2024 | | 2024 |
| Masked il12 fusion proteins and methods of use thereof G Volkers, TS VON KREUDENSTEIN, N AFACAN, G DESJARDINS, ... | | 2024 |
| 1396 TriTCE CPI: a novel trispecifc T cell engager platform with integrated PD-1/PD-L1 checkpoint inhibition engineered for the treatment of immunosuppressed tumors MM Verstraete, M Poffenberger, M Zago, V Luu, B Ma, N Escalante, J Li, ... Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |
| IMMUNOGLOBULIN Fc REGION VARIANTS COMPRISING STABILITY-ENHANCING MUTATIONS G Desjardins, E Escobar-Cabrera, A Samiotakis, GC Jones US Patent App. 17/999,477, 2023 | | 2023 |
| Masked il12 fusion proteins and methods of use thereof R Blackler, G Volkers, D Douda, TS VON KREUDENSTEIN, G Desjardins, ... US Patent App. 17/914,261, 2023 | | 2023 |
| PROTECTTM, a novel trispecific antibody masking platform with integrated immune modulation displays unique activity and differentiated modes of action A von Rossum, G Desjardins, N Escalante, W Wong, B Harbourne, J Li, ... Cancer Research 83 (7_Supplement), 2926-2926, 2023 | | 2023 |
| Masked il12 fusion proteins and methods of use thereof R BLACKLER, G VOLKERS, D DOUDA, TS VON KREUDENSTEIN, ... | | 2021 |
| Anti-pd-1/lag3 bispecific antibodies L FAYADAT-DILMAN, V Juan, S Khan, S HUANG, H Ying, EE CABRERA, ... | | 2019 |
| Études Structurales par Résonance Magnétique Nucléaire (RMN) du Site Actif du Ribozyme VS de Neurospora G Desjardins-Séguin | | 2009 |
